skip to content

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.